trial

Safety and Effectiveness of D-serine in Schizophrenia

NCTId NCT00322023
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 55 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2009-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
55 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2006-03
Primary completion
2009-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
D-serine

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Daniel C. Javitt, MD, PhDPrincipal Investigator

Sites

3 total
New Haven, United StatesGlen Oaks, United StatesOrangeburg, United States

Linked catalysts

1
Safety and Effectiveness of D-serine in Schizophrenia — primary completion2009-01

Facts & assertions

4 sourced
Enrollment
55
Phase
PHASE2
Primary Completion Date
2009-01
Status
COMPLETED
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Daniel C. Javitt, MD, PhD
person